Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for EKIMAS Corporation (ASNB : OTC)
 
 • Company Description   
ADVANSOURCE BIOMATERIALS CORPORATION develops advanced polymer materials which provide critical characteristics in the design and development of medical devices. The Company's biomaterials are used in devices that are designed for treating a broad range of disease states and anatomical sites. AdvanSource's business model leverages its proprietary materials science technology and manufacturing expertise in order to expand its product sales and royalty and license fee income. The Company has developed CardioPass, a synthetic coronary bypass graft, which is currently in a clinical trial in Europe.

Number of Employees: 0

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.25 Daily Weekly Monthly
20 Day Moving Average: 423 shares
Shares Outstanding: 0.51 (millions)
Market Capitalization: $0.64 (millions)
Beta: 0.08
52 Week High: $2.50
52 Week Low: $0.73
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -16.67% -9.06%
12 Week 8.70% 14.44%
Year To Date 23.15% 43.55%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3651 Lindell Road Suite D565
-
Las Vegas,NV 89103
USA
ph: 424-256-8560
fax: 978-657-0074
investors@advbiomaterials.com http://www.advbiomaterials.com
 
 • General Corporate Information   
Officers
Michael F. Adams - Chief Executive Officer and President
William J. O'Neill - Chairman
Michael L. Barretti - Director
Mark Tauscher - Director
Mark Tauscher - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 28265K205
SIC: 3841
Fiscal Year
Fiscal Year End: March
Last Reported Quarter: 12/01/21
Next Expected EPS Date: 09/28/22
Share - Related Items
Shares Outstanding: 0.51
Most Recent Split Date: 3.00 (0.02:1)
Beta: 0.08
Market Capitalization: $0.64 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 09/28/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 13.32
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 100.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -2,520.75
09/30/21 - -742.25
ROA
03/31/22 - -
12/31/21 - -442.38
09/30/21 - -376.15
Current Ratio
03/31/22 - -
12/31/21 - 1.65
09/30/21 - 0.03
Quick Ratio
03/31/22 - -
12/31/21 - 1.65
09/30/21 - 0.03
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - -
12/31/21 - 0.08
09/30/21 - -0.20
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - 0.00
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - 0.00
09/30/21 - -
 

Powered by Zacks Investment Research ©